Tel.: +33 (0)9 72 56 94 99

Meet Inoviem Scientifc at the 9th Congress of the European Crohn’s and colitis organization in Coppenhagen.

In collaboration with Erlangen and Ingolstadt hospitals, Inoviem Scientific has realized a longitudinal study for the prediction of response to anti-TNF therapy with 37 patients suffering from IBD, using its cutting-edge technology, PIMS®.

Results of this longitudinal study will be presented on the 20th of February at the 9th congress of the European Chron’s and Colitis Organisation (ECCO) in Coppenhagen.